A

Aptose Biosciences Inc
NASDAQ:APTO

Watchlist Manager
Aptose Biosciences Inc
NASDAQ:APTO
Watchlist
Price: 2.01 USD 17.54% Market Closed
Market Cap: 3.2m USD

Relative Value

There is not enough data to reliably calculate the relative value of APTO.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

APTO Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
vs History
vs Industry
Median 3Y
-0.9
Median 5Y
-4.7
Industry
23.7
Forward
-0
vs History
vs Industry
Median 3Y
-1
Median 5Y
-5.5
Industry
22.6
vs History
vs Industry
Median 3Y
-1
Median 5Y
-5.5
Industry
25.7
vs History
vs Industry
0
Median 3Y
-0.4
Median 5Y
11.4
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.4
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-4.1
Industry
5.9
Forward
-0.2
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-4.1
Industry
6.4
Forward
-0.2
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-4.9
Industry
8.2
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-4.9
Industry
6.4
vs History
57
vs Industry
22
Median 3Y
4.6
Median 5Y
9.5
Industry
5.8

Multiples Across Competitors

APTO Competitors Multiples
Aptose Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Aptose Biosciences Inc
NASDAQ:APTO
3.2m USD 0 -0.1 -0.1 -0.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 178 916.3 -162 447.3 -197 262.9 -195 011.9
US
Abbvie Inc
NYSE:ABBV
378.8B USD 6.4 161.3 15.7 22.3
US
Amgen Inc
NASDAQ:AMGN
177.8B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD 5.3 19.1 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 9.6 30.5 22.3 23.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 061.2 -526 -572.7 -557.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD 5.4 16.9 16 18.2
AU
CSL Ltd
ASX:CSL
85B AUD 3.7 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.7 32.1 55.1 56.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD 14.8 1 086.8 146.4 177.6
P/S Multiple
Revenue Growth P/S to Growth
CA
A
Aptose Biosciences Inc
NASDAQ:APTO
Average P/S: 3 418 104.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 178 916.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 061.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.8
46%
0.3
P/E Multiple
Earnings Growth PEG
CA
A
Aptose Biosciences Inc
NASDAQ:APTO
Average P/E: 173.9
Negative Multiple: -0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 447.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
161.3
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.1
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 086.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
A
Aptose Biosciences Inc
NASDAQ:APTO
Average EV/EBITDA: 37.4
Negative Multiple: -0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 262.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.1
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
146.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
A
Aptose Biosciences Inc
NASDAQ:APTO
Average EV/EBIT: 43.1
Negative Multiple: -0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 011.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
30%
0.7
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
56.7
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
177.6
N/A N/A